Product Details
Synonyms
CD40, Bp50, CDW40, MGC9013, TNFRSF5, p50
Source
Alexa Fluor 647-Labeled Human CD40 Protein, Fc Tag (CD0-HA256) is produced via site-specific conjugation of AF647 to Human CD40 Protein, Fc Tag under optimal conditions with a proprietary technology. Alexa Fluor 647-Labeled Human CD40 Protein, Fc Tag is expressed from human 293 cells (HEK293). It contains AA Glu 21 - Arg 193 (Accession # P25942-1).
Predicted N-terminus: Glu 21
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 47.1 kDa.
Conjugate
AF647
Excitation Wavelength: 640 nm
Emission Wavelength: 672 nm
Application
Please note that this product is NOT compatible to streptavidin detection system.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, 0.5% BSA, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-FACS

5e5 of 293T-CD40L cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of Alexa Fluor 647-Labeled Human CD40 Protein, Fc Tag (Cat. No. CD0-HA256) and negative control protein respectively. Alexa 647 signal was used to evaluate the binding activity (QC tested).
Protocol
Customer Reviews Writing Reviews

Background
Recent Advances
- English Name:
Tumor necrosis factor receptor superfamily member 5
- Category:
- Approved Drugs:
0 Details
- Drugs in Clinical Trials:
46 Details
- Highest Development Stage:
Phase 3 Clinical
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521



















